<DOC>
	<DOCNO>NCT02783482</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy Pharmacokinetics Immune Globulin Intravenous ( Human ) GC5107 subject Primary Humoral Immunodeficiency ( PHID ) .</brief_summary>
	<brief_title>Study Immune Globulin Intravenous ( Human ) GC5107 Subjects With Primary Humoral Immunodeficiency</brief_title>
	<detailed_description>This prospective , open-label , single-arm , historically control , multicenter phase 3 study measure safety , efficacy pharmacokinetics tolerability GC5107 subject Primary Humoral Immunodeficiency disease ( PHID ) . Subjects receive intravenous infusion investigational product dose interval use previous Immunoglobulin intravenous ( IGIV ) maintenance therapy . GC5107 administer every 21 28 day period 12 month .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Subject confirm clinical diagnosis Primary Humoral Immunodeficiency Disease define IUIS ( International Union Immunological Societies ) require treatment IGIV . Documented agammaglobulinemia hypogammaglobulinemia ( preferably document antibody deficiency ) Male Female , age 2 70 year The subject receive 300900 mg/kg license IGIV therapy 21 28 day interval least 3 month prior study At least 2 documented IgG trough level â‰¥ 500 mg/dL obtain two infusion cycle ( 21 28 day ) within 12 month prior study enrollment Subject secondary immunodeficiency Subject newly diagnose PHID yet treat immunoglobulin Subject diagnose dysgammaglobulinemia isolate IgG subclass deficiency isolate IgA deficiency know antiIgA antibody History reaction hypersensitivity IGIV injectable form IgG Subject lifetime history least one thrombotic event include deep vein thrombosis , cerebrovascular accident , pulmonary embolism , transient ischemic attack , myocardial infarction Subject receive blood product human albumin human immunoglobulin within 12 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>